Our office bpv BRAUN PARTNERS played a leading role in this international transaction and provided comprehensive legal advice and assistance in the preparation and execution of the transaction (led by A&O Shearman, Paris, with the counterparty CMS Prague), including due diligence.
The legal advice, due diligence, and transaction support were provided by a team led by partner Arthur Braun, supported by lawyers Markéta Kleinová, Evelina Weagová, Nikola Faltová, and Nikola Ourodová. Arthur Braun, partner at bpv BRAUN PARTNERS, evaluates the successful transaction as follows: “A big thank you to our entire legal team who participated in the entire transaction. Thanks to this acquisition, Europlasma will own and operate 24 plasma collection centers in Central Europe and 15 centers in the Czech Republic. This will significantly increase Europlasma’s plasma collection capacity and also contribute to ensuring plasma supply for LFB’s medicine production.”
LFB, a French biotechnology company, develops, manufactures, and markets medicinal products derived from plasma and recombinant proteins for the treatment of patients with serious and often rare diseases. LFB remains committed to its strategy of increasing plasma collection capacity in Europe to provide plasma-derived medicines and meet the growing needs of patients in Europe. LFB also plans to offer its products to patients in the Czech Republic.
The plant will double its capacity to 108 MW thanks to a new fast-start gas turbine to be delivered to UCED Elektrárny Prostějov by General Electric.
Several proposals for implementing regulations in the energy sector have been published in recent days:
The Government approved an amendment to Act No. 334/1992 Coll., on the Protection of the Agricultural Land Fund, which strengthens the protection of agricultural land.
